These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 23021975

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R, Quarantelli M, Bonavita S, Ventrella G, Lus G, Vacca G, Prinster A, Orefice G, Tedeschi G, Brescia Morra V.
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [Abstract] [Full Text] [Related]

  • 4. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A, Bianchi MR, Deotto L, Benedetti MD.
    Eur Neurol; 2014 Nov; 72(3-4):173-80. PubMed ID: 25226868
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V.
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients.
    Kerbrat A, Le Page E, Leray E, Anani T, Coustans M, Desormeaux C, Guiziou C, Kassiotis P, Lallement F, Laplaud D, Diraison P, Rouhart F, Sartori E, Wardi R, Wiertlewski S, Edan G.
    J Neurol Sci; 2011 Sep 15; 308(1-2):98-102. PubMed ID: 21665227
    [Abstract] [Full Text] [Related]

  • 10. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L, Giannì C, Barletta V, Mancinelli C, Fubelli F, Borriello G, Pozzilli C.
    J Neurol Sci; 2012 Dec 15; 323(1-2):104-12. PubMed ID: 23006974
    [Abstract] [Full Text] [Related]

  • 11. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.
    Ghezzi A, Pozzilli C, Grimaldi LM, Moiola L, Brescia-Morra V, Lugaresi A, Lus G, Rinaldi F, Rocca MA, Trojano M, Bianchi A, Comi G, Filippi M, Italian MS Study Group.
    Mult Scler; 2013 Jul 15; 19(8):1106-12. PubMed ID: 23401129
    [Abstract] [Full Text] [Related]

  • 12. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 Jul 15; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 13. Failure of natalizumab to prevent relapses in neuromyelitis optica.
    Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O, Neuromyelitis Optica Study Group.
    Arch Neurol; 2012 Feb 15; 69(2):239-45. PubMed ID: 22332191
    [Abstract] [Full Text] [Related]

  • 14. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
    Fernández O, Alvarenga MP, Guerrero M, León A, Alonso A, López-Madrona JC, Leyva L, Oliver B, de Ramón E, Luque G, Fernández V.
    Mult Scler; 2011 Feb 15; 17(2):192-7. PubMed ID: 21088044
    [Abstract] [Full Text] [Related]

  • 15. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.
    Kallweit U, Jelcic I, Braun N, Fischer H, Zörner B, Schreiner B, Sokolov AA, Martin R, Weller M, Linnebank M.
    Clin Neuropharmacol; 2012 Feb 15; 35(2):77-80. PubMed ID: 22318192
    [Abstract] [Full Text] [Related]

  • 16. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study.
    Alroughani R, Ahmed SF, Behbehani R, Al-Hashel J.
    Pediatr Neurol; 2017 May 15; 70():56-60. PubMed ID: 28389054
    [Abstract] [Full Text] [Related]

  • 17. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R.
    Lancet Neurol; 2009 Mar 15; 8(3):254-60. PubMed ID: 19201654
    [Abstract] [Full Text] [Related]

  • 18. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.
    O'Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N.
    Neurology; 2011 May 31; 76(22):1858-65. PubMed ID: 21543733
    [Abstract] [Full Text] [Related]

  • 19. Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis.
    Fernández-Megía MJ, Casanova B, Magraner MJ, Font-Noguera I, Poveda-Andrés JL.
    Farm Hosp; 2011 May 31; 35(2):75-9. PubMed ID: 20685144
    [Abstract] [Full Text] [Related]

  • 20. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
    Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L.
    JAMA Neurol; 2014 Aug 31; 71(8):954-60. PubMed ID: 24977406
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.